



2007 first-quarter sales

Analyst & Media Conference Call
Basel, 3 May 2007

COMMITTED TO
SIMPLY DOING MORE
FOR DENTAL PROFESSIONALS

Disclaimer

This presentation contains certain “forward-looking statements”, which can be identified by use of terminology such as “expect”, “expectation”, “intend”, “continue”, “achieve”, “maintain”, “improve”, “foresee”, “anticipate”, “product innovations”, “outlook”, “forecast”, or similar wording. Such forward-looking statements reflect the current views of management and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results, performance or achievements of the Group to differ materially from those expressed or implied herein. Should such risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation. Straumann is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements contained in it as a result of new information, future events or otherwise.

Agenda

1. Highlights

2. Q1 revenues

3. Operational achievements and outlook

4. Q&A

Highlights – important strategic milestones achieved

- Net revenue grows 12% in l.c./CHF on high Q1 06 baseline to CHF 179 million
- US core implant business accelerates to low-teen growth
- Strategic acquisition of etkon; ensures presence in fast-growing CAD/CAM tooth replacement market
- Expansion of direct distribution continued: memorandum of understanding signed with Japanese distributor; letter of intent signed with Korean distributor
- Highly successful ITI World Symposium, IDS and AO meetings
- Executive Vice President of Global Sales hired

Agenda

1. Highlights


2. Q1 revenues

3. Operational achievements and outlook


4. Q&A

Growth by region

Q1 2007 net revenue growth by region
Group: 12% (l.c.), 12% (CHF)




Q1 2007 net revenue by region
(Total: CHF 179 million)




Net revenue impacted by exceptionals

Contribution to Q1 2007 net revenue growth in %




2006-2007 organic growth by quarter in % I.c.




Base-line effects on regional growth


Europe: growth in % I.c.




North America: growth in % I.c.



Asia/Pacific: growth in % CHF



RoW: growth in % CHF



Agenda

1. Highlights

2. Q1 revenue review

3. Operational achievements and outlook

4. Q&A

Entry into CAD/CAM tooth restoration through acquisition of etkon

- A unique partner in the dental sector, offering surgical, restorative and regenerative solutions
- Straumann gains immediate presence in state-of-the-art CAD/CAM crown and bridge dentistry including high-end ceramics
- 77% of etkon shares acquired in March 2007 for € 77 million; remainder to follow bringing total consideration to € 100 million
- etkon sales of CHF 2 million booked in March
- Impressive scanner sales at IDS
- 5-D Highspeed production technology launched at IDS

Going direct in key Asian markets



Japan

- Memorandum of understanding signed with distributor to acquire Straumann business in Japan
- Japan is third largest global market in terms of sales

Korea

- Letter of intent signed with distributor
- Second largest Asian market in terms of sales
- Contributes approx. 15% of Straumann's regional revenues

Both transactions

- Expected to close Q3 2007

FDA re-inspection awaited

Recap

- FDA observations mostly concern maintenance of quality system documentation and procedures at Biora
- ‘Dental bone grafting materials’ subject to US import detention until issues are resolved

New


- FDA review of company’s response to warning letter completed; ‘responses appear to be adequate’
- Re-inspection required; process for scheduling started but could take several months until completion; timing/outcome of re-inspection will determine how soon Biora products can be imported into the US again

ITI World Symposium - the pinnacle of science in implant dentistry and oral tissue regeneration

- 3000 participants from around the world (sold out)
- High caliber research and clinical experience reports
- Initial clinical reports on bone-level implant
- Positive results reported from multicenter randomized controlled clinical trials on Straumann BoneCeramic and Membrane



New bone level implant line extension highly promising



- Promising results from pre-clinical and clinical studies
- Large, systematic clinical program in progress
- Intermediate 6-month data on 20+ patients show excellent hard and soft tissue results
- Launch expected in early 2008
- Gives Straumann access to a significant market segment: every implant option with Straumann simplicity and unique benefits of SLActive

Outlook and 2007 guidance

Barring unforeseen circumstances, Straumann foresees 2007 full-year net revenue growth of around 18% in local currencies, excluding the recently acquired etkon business. North American growth will be constrained until the import detention on Biora products in the US is resolved, while additional lift is expected to come from the foreseen distribution acquisitions in Japan and Korea later in the year.

Excluding acquisitions, full-year operating and net profit margins are expected to reach 29-30% and 24-25% respectively.

Agenda

1. Highlights
2. Q1 revenue review
3. Operational achievements and outlook

4. Q&A

Important dates

Business reporting dates

8 August	H1 results
28 September	Investor day, Andover
2 November	9M and Q3 sales

Detailed calendar in Annual Report

Roadshows &
investor meetings

Selected congresses

CALENDAR
KEY REPORTING DATES IN 2007
7 February: 2006 full-year results
30 March: Annual General Meeting
3 May: Q3 sales
9 August: Q3 sales and 9M results
2 November: Q3 and 9M sales
PLANNED INVESTOR RELATIONS EVENTS AND CONFERENCES IN 2007
Members of Straumann's Executive Management and/or Investor Relations team plan to take part in the following events, subject to availability.
19 February: Roadshow, UBS, Zurich
20 February: Roadshow, Credit Suisse, London
21 February: Roadshow, Bank Sarasin, Dublin
22 February: Roadshow, Kepler Equities, Frankfurt
23 February: Roadshow, Charvexus, Paris
20 March: Reverse roadshow, Citigroup, Basel
27 March: Morgan Stanley, Swiss Biotech and Medtech Trip, Basel
29 March: Kepler Equities, Small and Mid Cap Seminar, Zurich
24 April: Roadshow, TransAtlantic II, New York
15-16 May: Merrill Lynch, 4th Annual Pan-European Med Tech Conference, London
Early June: Reverse roadshow, Charvexus, Basel
22-23 August: UBS, Swiss Mid Cap Conference, Zurich
13 August: Roadshow, Vontobel, Zurich
14 August: Roadshow, Merrill Lynch, London
15 August: Roadshow, Helvea, Edinburgh
16 August: Roadshow, Vontobel, Paris
17 August: Roadshow, Frankfurt
5-6 September: Goldman Sachs, European Medtech and Healthcare Services Conference, London
26-27 September: UBS Life Science/Credit Suisse Swiss Equities, New York
Early November: Reverse roadshow, Vontobel, Health Care Days, Basel
29 November: Credit Suisse, Swiss Health Care Conference, Zurich
SELECTED DENTAL MEETINGS IN 2007
15-17 February: 9th World Congress of Osseointegration, Venice, Italy
20-24 March: International Dental Show (IDS) 2007, Cologne, Germany
21-24 March: 8th Meeting of the International Association for Dental Research, New Orleans, USA
25-29 April: 19th Asia Pacific Dental Congress, Jakarta, Indonesia
26-28 April: ITI World Symposium, New York, USA
10-12 May: International Orthology Symposium, Monaco
5-7 October: 3rd European Conference on the Reconstruction of the Periodontally Diseased Patient, Paris, France
24-27 October: FDI World Dental Congress, Dubai, U.A.E.
25-27 October: 16th Annual European Association for Osseointegration (EAO) Congress, Barcelona, Spain
29 November - 1 December: Gemeinschaftskongress DGI, ÖGOCI, SGI, Vienna, Austria